Mumbai: BMC has waved the tender to get the first Covid-19 anti-virus pill molnupiravir which was approved by Indian drug regulators on December 28.
This drug has been prescribed in the private sector because it is available last Friday.
Thirteen Indian drug makers arranged to produce oral drugs that have been developed by Biototapeutika companies based in the US in collaboration with Merck.
In India, it has been approved based on authorization of emergency use to treat adults with Covid-19 “which has a high risk of developments”.
This is especially for mild to moderate cases.
“The central purchasing department has ordered 10,000 bottles,” said Suresh Kakani, an additional municipal commissioner.
Some covid city centers get drugs with corporate social responsibility immediately.
Dr.
Neelam Andrade, the Dean of Nesco Covid Center at Goregaon, said he had been sure of a dose that could support the treatment of 15 patients.
“We must have medicine with us in one or two days,” he said.
Care is a five-day course where a patient must take four pills every day.
This is not authorized to be used in patients younger than 18 years.
Dr.
Vasant Nagveyar, a contagious disease consultant at the Lilavati Hospital and members of the Covid Task Force, said he had prescribed him to 20 patients since Friday.
A five-day Molnupiravir course is likely to cost Rs 2,500-Rs 3,000.
BMC floats tender for the first covid pill Molnupiravir
